Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Triple Negative Breast Cancer

Join Harold Burstein, MD, PhD (Medical Oncologist) and Jennifer Bellon, MD (Radiation Oncologist) as they present their multidisciplinary expertise on a range of cases pertaining to triple negative breast cancer.

Since patients are heterogeneous, patient management should also be individualized. The cases in this webinar are designed to highlight significant clinical decision points concerning treatment selection, toxicity management, and areas of recent change or controversy in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) while reinforcing emerging data from clinical trials. This webinar will allow learners to understand how to apply the standards of care to their practice and healthcare setting.

Triple negative breast cancers (negative for hormone receptors and HER2) can be highly aggressive and marked by high rates of relapse, visceral and CNS metastases, and early death. These tumors can be resistant to chemotherapy and clinically established targeted therapies have not been identified.  In the NCCN Guidelines®, systemic chemotherapy is often recommended to prevent a recurrence of disease. Selecting an appropriate therapy is a challenge.


Course details

  • Health Care Other: 1.00
  • Nurse: 1.00
  • Pharmacist: 1.00
  • Physician: 1.00
  • Event starts: Thu, May 23 2013 - 1:00 pm
  • Event ends: Thu, May 23 2013 - 2:00 pm
  • Course opens: Thu, May 23 2013
  • Course expires: Fri, Aug 02 2013

Target audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning objectives

Following this webinar, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for triple negative breast cancer in the treatment of patients.
  • Describe the multidisciplinary aspects of patient management for triple negative breast cancer.
  • Identify the key characteristics for triple negative breast cancer that trigger decision points.
  • Recognize situations where optimal care may require adapting the guideline recommendations to individual circumstances.


Jennifer Bellon, MD
Harvard Medical School
Dana-Farber/Brigham and Women’s Cancer Center
Boston, Massachusetts

Harold Burstein, MD, PhD
Harvard Medical School
Dana-Farber/Brigham and Women’s Cancer Center
Boston, Massachusetts


This activity is supported by educational grants from:

  • Daiichi Sankyo, Inc.
  • Genentech
  • Millennium: The Takeda Oncology Company
  • Novartis Pharmaceuticals Corporation
  • Teva Pharmaceuticals

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This activity is supported by a grant from Onyx Pharmaceuticals.

This activity closed on August 2nd, 2013 and is no longer available for enrollments.